Hiroyuki Ueno's work at Kyoto University's venture fund has been rewarded with a promotion to senior officer and executive manager.
Kyoto University Innovation Capital (Kyoto-iCap), the institution’s venture fund, has promoted its investment manager Hiroyuki Ueno to executive manager and senior officer.
Having joined Kyoto-iCap in 2016, Ueno currently supports six of the unit’s portfolio companies, including neuropathic pain developer AlphaNavi Pharma, a collaboration with pharmaceutical firm Sumitomo Dainippon Pharma.
Ueno had worked at Sumitomo Dainippon as a fellow and manager within the DSP Cancer Institute from 2012 until 2016.
His other Kyoto iCap projects are oncology drug developer Chordia Therapeutics, tinnitus treatment device business CleanHearing, medical diagnostics developer DrawBridge Health, drug development, research and consulting services provider Kola-Gen Pharmaceuticals and cancer drug developer Thyas.
Earlier in his career, Ueno worked for another pharmaceutical company – Takeda – from 2002 until 2011, initially as a scientist, before a promotion to principal scientist in 2005.
His research at Takeda included devising a drug discovery system for RNA binders, and a paper on the neurological pathway for modulating the body’s urethra closure response.
Ueno had previously been with pharmaceutical firm Organon International as a research scientist from 2001 until 2002, tasked with finding basic gene expression suppression technologies.
– Image courtesy of LinkedIn
